deltatrials

Eosinophilic asthma Trials in Miami, United States

Conditions / Eosinophilic asthma / Miami, United States

Clinical trials for Eosinophilic asthma investigate a range of treatment strategies and patient populations.

12 total trials for this combination

Showing top 10 of 12 trials

Trials

NCT ID Title Status Phase
NCT01290887 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma TERMINATED PHASE3
NCT05748600 A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma ACTIVE_NOT_RECRUITING PHASE3
NCT01270464 A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma COMPLETED PHASE3
NCT06750289 Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment RECRUITING PHASE3
NCT04046939 Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma COMPLETED PHASE2
NCT01285323 A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma COMPLETED PHASE3
NCT01508936 Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma COMPLETED PHASE3
NCT05813288 A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) TERMINATED PHASE3
NCT05763121 A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma. TERMINATED PHASE3
NCT01287039 A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma COMPLETED PHASE3

Related Pages